Pharmaceuticals
MediLink Therapeutics closes US$70 million Series B financing
SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of aUS$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highligh...
SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research
The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) an...
NuclixBio Announces a Collaborative Research Agreement with PharmAbcine
SEOUL, South Korea, March 14, 2022 /PRNewswire/ -- NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech...
111, Inc. Becomes First Online Retail Platform for BGI's SARS-CoV-2 Virus Antigen Detection Kits
SHANGHAI, March 14, 2022 /PRNewswire/ -- On March 14, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company signed a strategic cooperation agreement with Shenzhen BGI Co., Ltd. (SZ: 300676) under which BGI will supply its SARS-CoV-2 Virus Ant...
Clarivate Deals Report Highlights Emerging Trends in Biopharma Deal-Making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology related deals dominate the landscape Biotech companies in U.S. awarded largest sums of capital, followed by Mainland China and UK LONDON, March 14, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in provid...
Hexvix® Has Obtained CDE Approval for the Inclusion In the Clinical Real-world Evidence Pilot Study
SHANGHAI, March 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that the Hainan Provincial Medical Products...
Impact Therapeutics Announces Completion of Series D1 Financing
SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors that par...
CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer
* GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved inChina for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC) * The labeled indications of GAVRETO have been expanded after it was approved by...
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
SHANGHAI, March 14, 2022 /PRNewswire/ -- Everest Medicines
Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year
HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, HKEX: 1672) today announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the domesti...
NMPA Clears IND for First T-Cell Receptor (TCR) T Cell Therapy to Treat Hepatitis B virus (HBV) associated hepatocellular carcinoma (HCC)
SINGAPORE, March 11, 2022 /PRNewswire/ -- Singapore-based SCG Cell Therapy Pte Ltd ("SCG"), a leading biotechnology company, today announced that the China National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for SCG101, the company's first T-...
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18
BEIJING and BRIDGEWATER, N.J., March 11, 2022 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, sing...
Novavax Announces Launch of Global Vaccine Education Programs
- 'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines - Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company de...
THE WORLD'S FIRST ACADEMIC PAPER ON THE POTENTIAL USE OF VIRTUAL REALITY IN MODULATING PSYCHEDELIC-ASSISTED PSYCHOTHERAPY PUBLISHED BY THE CO-FOUNDERS OF ENOSIS THERAPEUTICS
The Peer-Reviewed Article Published In Volume 13 March 2022 Issue Of Frontiers In Psychology Journal Is A Landmark Examination Of Virtual Reality Therapy Combined With Psychedelic Therapy. MELBOURNE, Australia, March 10, 2022 /PRNewswire/ -- The world's first scientific paper offering a careful...
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
SHANGHAI, March 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1 (Cefepime Rescue with Taniborbactam in cUTI), evaluating cefepime-taniborbactam, an in...
Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress
SUZHOU, China, March 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Transcenta has ...
Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting
* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinical data suggests that BBT-207 may have the potential to be positioned as a frontline treatment with the anti-tumor effects in EGFR mutant NSCLC SEONGNAM, South Korea, March 9, 2022 /PRNewswire/ -- B...
Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis
- Cystinosis is a rare genetic disease affecting 1 in 100,000-200,000 live births and poses a lifelong risk to those affected. Cystinosis slowly destroys the body's organs including the kidneys, eyes, thyroid, muscles, liver, pancreas, gonads, and brain. - There are currently no curative treatme...
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational r...
Kusum Healthcare recognized as one of Best Places to Work in Philippines for 2022
MANILA, Philippines, March 9, 2022 /PRNewswire/ -- Kusum Healthcare, a leading tech-driven pharmaceutical group, has been recently awarded the Best Place to Work certification inPhilippines for 2022. During the company assessment, 97% of employees recommended the organization illustrating the com...
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00